Bd reports q2 fiscal 2025 results; raises eps despite macro headwinds

financial highlights
- revenue: $5.3 billion (up 4.5% as reported, 6.0% currency-neutral, 0.9% organic)
- gaap eps: $1.07
- adjusted eps: $3.35
- margin expansion and operational efficiency drove earnings beat despite soft organic growth

strategic and operational updates
- bd to invest $2.5 billion over 5 years to expand u.s. manufacturing, reinforcing domestic supply resilience
- bd pyxis™ medstation es and alaris™ infusion system won 2025 best in klas awards, highlighting market leadership in medication management
- launch of hemosphere alta™ platform brings ai-driven clinical decision support to advanced patient monitoring
- fda clearance for phasix™ st umbilical hernia patch, first of its kind in bioabsorbable mesh
- clinical milestone for galaflex lite™ scaffold in breast implant revision surgery with first patient treated
- diagnostics unit gains fda clearance for integrated solution to detect antimicrobial resistance using bd phoenix™, bdxpert™, and synapsys™ informatics

guidance and outlook
- company reaffirmed full-year eps guidance; detailed tariff-related headwinds in updated projections
- bd continues to prioritize innovation and efficiency under its bd excellence operating model

BD announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share.

BD launches industry-first bioabsorbable mesh for umbilical hernia repair

BD (Becton, Dickinson and Company) announced FDA 510(k) clearance and commercial launch of the Phasix ST Umbilical Hernia Patch, the first fully absorbable mesh specifically designed for umbilical hernias. Composed of the bioabsorbable polymer Poly-4-hydroxybutyrate (P4HB) and incorporating Sepra Technology, the patch mimics the technique and function of permanent mesh while offering a fully absorbable alternative.

Surgeons can deploy the new patch using the same method as traditional permanent mesh, making it easier to adopt in existing surgical workflows. The design enhances placement and fixation through a pocket and strap mechanism, modeled after the widely used Ventralex ST Hernia Patch.

Recent survey data cited by BD shows that 60% of patients prefer non-permanent mesh, and over 70% of surgeons are willing to consider patient preferences. The new product extends BD’s Phasix Mesh portfolio, which has over 385,000 implants globally and is backed by more than 85 clinical publications.

BD emphasized its commitment to innovation in tissue repair and the continued development of advanced biomaterials for improved patient outcomes. The Phasix ST Umbilical Patch is available in three sizes to support a range of hernia repair needs.

BD Launches AI-Powered Hemodynamic Monitoring Platform to Improve Critical Care Outcomes

Becton, Dickinson and Company (NYSE: BDX) has introduced HemoSphere Alta, its most advanced hemodynamic monitoring platform, featuring AI-driven clinical decision support tools designed to help clinicians anticipate and manage blood pressure instability in critical care settings.

The system integrates smart algorithms, including the newly developed Cerebral Autoregulation Index (CAI), a breakthrough parameter that helps determine whether a patient's brain can maintain stable blood flow under fluctuating blood pressure. When used in combination with the noninvasive ForeSight IQ and invasive Acumen IQ sensors, CAI offers personalized insights into cerebral perfusion needs.

HemoSphere Alta also includes BD's Acumen Hypotension Prediction Index (HPI), which has been validated in large studies for its ability to forecast hypotensive events before they occur, allowing clinicians to intervene sooner and potentially reduce the risk of organ damage or death.

The platform features a redesigned user interface with a 15-inch customizable touchscreen, split-screen display options, and voice and gesture controls to streamline workflows and maintain sterility in surgical environments.

“This platform combines predictive analytics with real-time monitoring to give clinicians unprecedented visibility into patient stability,” said Tim Patz, president of BD Advanced Patient Monitoring. “It’s a major step forward in enabling personalized, precision-guided hemodynamic care.”

The launch follows BD’s acquisition of Advanced Patient Monitoring and reinforces its commitment to developing connected care technologies that harness AI and data science to enhance clinical decision-making and patient safety.

BD Named Among America's Most Innovative Companies by Fortune

BD (Becton, Dickinson and Company) has been recognized by Fortune as one of America's Most Innovative Companies for 2025, placing in the top 25% of companies overall. This distinction celebrates BD’s commitment to developing groundbreaking medical technologies, improving operational processes, and nurturing an innovative corporate culture.

The ranking is based on surveys conducted with over 40,000 U.S. employees and more than 2,500 industry experts, evaluating companies across three dimensions: product innovation, process innovation, and innovation culture.

Tom Polen, BD’s chairman, CEO and president, highlighted the company's dedication to continuous innovation and improvement, emphasizing its impact on billions of patients worldwide and its role in delivering cutting-edge medical devices.

For more details about BD’s awards and achievements, visit news.bd.com/Award-news.

BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025.

Becton, Dickinson and Company (BD) announced that the first patient has been treated in its clinical trial for the GalaFLEX LITE™ Scaffold, an investigational device aimed at reducing the recurrence of capsular contracture in breast implant revision surgery. The trial is a key step toward Premarket Approval from the U.S. Food and Drug Administration.

Capsular contracture is a common complication of implant-based breast surgery, occurring in 10 to 20 percent of cases and requiring surgical intervention in advanced stages. The recurrence rate after surgery can be as high as 54 percent. The BD STANCE Study (NCT05945329) is a multi-center, randomized controlled trial designed to assess the effectiveness of GalaFLEX LITE™ Scaffold, a bioabsorbable polymer implant made of Poly-4-Hydroxybutyrate (P4HB), in reducing capsular contracture recurrence and improving implant positioning.

The trial, which will enroll at least 250 patients across 40 sites, is being conducted with the FDA’s collaboration and will compare GalaFLEX LITE™ with conventional revision surgery. Patients will be randomized 2:1, receiving either the scaffold or standard care without additional supportive materials.

BD aims to establish GalaFLEX LITE™ as a transformative biomaterial for soft tissue reconstruction. The company is committed to scientific rigor and patient safety, with continued FDA engagement to expand women’s healthcare solutions.

For more details, visit www.galateasurgical.com.

Becton, Dickinson and Company (BD) held its 2025 Annual Meeting on January 28, 2025. Shareholders elected all board nominees for a one-year term. Ernst & Young was ratified as the independent auditor for fiscal year 2025. Shareholders also approved executive compensation on an advisory basis.